Clinical Trial Update: A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation safety study of I5NP in patients undergoing major cardiovascular surgery, sponsored by Quark Pharmaceuticals; the trial evaluated safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Renal Failure

Drugs mentioned

• I5NP (I5NP)

Snippet

Sponsor: Quark Pharmaceuticals | Conditions: Injury of Kidney, Acute Renal Failure | Phase 1 | Status: COMPLETED